Loading...
Loading...
AXGN| Name | Value |
|---|---|
| Revenues | 47.9M |
| Cost of Revenue | 12.6M |
| Gross Profit | 35.3M |
| Operating Expense | 35.8M |
| Operating I/L | -0.4M |
| Other Income/Expense | -1.5M |
| Interest Income | 0.0M |
| Pretax | -1.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -1.9M |
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve damage, offering products such as Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and Avive Soft Tissue Membrane. These products provide off-the-shelf processed human nerve allografts, porcine submucosa extracellular matrix coaptation aids, and soft tissue membranes for nerve repair and protection. The company also offers the AxoTouch two point discriminator for measuring skin innervation density. AxoGen serves hospitals, surgery centers, and surgeons in the United States, Canada, Europe, South Korea, and internationally.
